TY - JOUR AU - Amr Ismail AU - Rocio Gavidia Quezada AU - Kenneth Iwuji AU - Abdussalam Shredi AU - Michelle Tarbox PY - 2018/01/19 Y2 - 2024/03/28 TI - Vancomycin and linear IgA bullous dermatosis JF - The Southwest Respiratory and Critical Care Chronicles JA - The Chronicles VL - 6 IS - 22 SE - Case Reports DO - 10.12746/swrccc.v6i22.445 UR - https://pulmonarychronicles.com/index.php/pulmonarychronicles/article/view/445 AB - Vancomycin is a broad-spectrum antibiotic that is considered an optimal parenteral treatment for many infections, including septicemia, pneumonia, cellulitis, endocarditis, and meningitis caused by methicillin-resistant Staphylococcus aureus. It is the first-line treatment for the increasing health care-associated infection Clostridium difficile pseudomembranous colitis. More side effects are being reported secondary to increased vancomycin use. Of those side effects, skin reactions are becoming more recognized by physicians.Keywords: Vancomycin, methicillin-resistant Staphylococcus aureus, linear IgA bullous dermatosis, vancomycin skin reactions ER -